In T2DM patients, treatment of empagliflozin for 24 weeks enhanced leukocyte antioxidative enzymes expression (glutathione s-reductase and catalase) and elevated serum anti-inflammatory cytokine interleukin 10 (IL-10) levels, with concomitant reduction of inflammatory markers, high sensitive C-reactive protein (hs-CRP) and myeloperoxidase [169]. Here, IL10 is linked to type 2 diabetes mellitus.